Literature DB >> 1618935

Imaging muscarinic cholinergic receptors in human brain in vivo with Spect, [123I]4-iododexetimide, and [123I]4-iodolevetimide.

H W Müller-Gärtner1, A A Wilson, R F Dannals, H N Wagner, J J Frost.   

Abstract

A method to image muscarinic acetylcholine receptors (muscarinic receptors) noninvasively in human brain in vivo was developed using [123I]4-iododexetimide ([123I]IDex), [123I]4-iodolevetimide ([123I]ILev), and single photon emission computed tomography (SPECT). [123I]IDex is a high-affinity muscarinic receptor antagonist. [123I]ILev is its pharmacologically inactive enantiomer and measures nonspecific binding of [123I]IDex in vitro. Regional brain activity after tracer injection was measured in four young normal volunteers for 24 h. Regional [123I]IDex and [123I]ILev activities were correlated early after injection, but not after 1.5 h. [123I]IDex activity increased over 7-12 h in neocortex, neostriatum, and thalamus, but decreased immediately after the injection peak in cerebellum. [123I]IDex activity was highest in neostriatum, followed in rank order by neocortex, thalamus, and cerebellum. [123I]IDex activity correlated with muscarinic receptor concentrations in matching brain regions. In contrast, [123I]ILev activity decreased immediately after the injection peak in all brain regions and did not correspond to muscarinic receptor concentrations. [123I]IDex activity in neocortex and neostriatum during equilibrium was six to seven times higher than [123I]ILev activity. The data demonstrate that [123I]IDex binds specifically to muscarinic receptors in vivo, whereas [123I]ILev represents the nonspecific part of [123I]IDex binding. Subtraction of [123I]ILev from [123I]IDex images on a pixel-by-pixel basis therefore reflects specific [123I]IDex binding to muscarinic receptors. Owing to its high specific binding, [123I]IDex has the potential to measure small changes in muscarinic receptor characteristics in vivo with SPECT. The use of stereoisomerism directly to measure nonspecific binding of [123I]IDex in vivo may reduce complexity in modeling approaches to muscarinic acetylcholine receptors in human brain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618935     DOI: 10.1038/jcbfm.1992.80

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  7 in total

Review 1.  Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology.

Authors:  G Stöcklin
Journal:  Eur J Nucl Med       Date:  1992

2.  Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography.

Authors:  J J Claus; E A Dubois; J Booij; J Habraken; J C de Munck; M van Herk; B Verbeeten; E A van Royen
Journal:  Eur J Nucl Med       Date:  1997-06

3.  Sequential 123I-iododexetimide scans in temporal lobe epilepsy: comparison with neuroimaging scans (MR imaging and 18F-FDG PET imaging).

Authors:  Armin Mohamed; Stefan Eberl; Michael J Fulham; Michael Kassiou; Aysha Zaman; David Henderson; Scott Beveridge; Chris Constable; Sing Kai Lo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-23       Impact factor: 9.236

4.  In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography.

Authors:  Adrian J Mogg; Thomas Eessalu; Megan Johnson; Rebecca Wright; Helen E Sanger; Hongling Xiao; Michael G Crabtree; Alex Smith; Ellen M Colvin; Douglas Schober; Donald Gehlert; Cynthia Jesudason; Paul J Goldsmith; Michael P Johnson; Christian C Felder; Vanessa N Barth; Lisa M Broad
Journal:  J Pharmacol Exp Ther       Date:  2018-04-11       Impact factor: 4.030

Review 5.  Update on PET Tracer Development for Muscarinic Acetylcholine Receptors.

Authors:  Marius Ozenil; Jonas Aronow; Marlon Millard; Thierry Langer; Wolfgang Wadsak; Marcus Hacker; Verena Pichler
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-02

6.  Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis.

Authors:  Geor Bakker; Claudia Vingerhoets; Daphne Boucherie; Matthan Caan; Oswald Bloemen; Jos Eersels; Jan Booij; Thérèse van Amelsvoort
Journal:  Neuroimage Clin       Date:  2018-03-03       Impact factor: 4.881

7.  Human biodistribution and internal dosimetry of 4-[ 18F]fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart.

Authors:  Cameron D Pain; Graeme J O'Keefe; Uwe Ackermann; Vincent Dore; Victor L Villemagne; Christopher C Rowe
Journal:  EJNMMI Res       Date:  2020-06-12       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.